Title |
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|
---|---|
Published in |
The Lancet, February 2013
|
DOI | 10.1016/s0140-6736(12)61763-2 |
Pubmed ID | |
Authors |
Mathias J Rummel, Norbert Niederle, Georg Maschmeyer, G Andre Banat, Ulrich von Grünhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz Dürk, Harald Ballo, Martina Stauch, Fritz Roller, Juergen Barth, Dieter Hoelzer, Axel Hinke, Wolfram Brugger, on behalf of the Study group indolent Lymphomas |
Abstract |
Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma. Bendamustine plus rituximab is effective for relapsed or refractory disease. We compared bendamustine plus rituximab with CHOP plus rituximab (R-CHOP) as first-line treatment for patients with indolent and mantle-cell lymphomas. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 7 | 24% |
Spain | 2 | 7% |
Italy | 1 | 3% |
Argentina | 1 | 3% |
Japan | 1 | 3% |
Turkey | 1 | 3% |
France | 1 | 3% |
Unknown | 15 | 52% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 23 | 79% |
Scientists | 4 | 14% |
Science communicators (journalists, bloggers, editors) | 1 | 3% |
Practitioners (doctors, other healthcare professionals) | 1 | 3% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 2 | <1% |
Ecuador | 2 | <1% |
United States | 2 | <1% |
Canada | 2 | <1% |
Switzerland | 1 | <1% |
Brazil | 1 | <1% |
Czechia | 1 | <1% |
United Kingdom | 1 | <1% |
Netherlands | 1 | <1% |
Other | 4 | <1% |
Unknown | 694 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 132 | 19% |
Other | 120 | 17% |
Student > Ph. D. Student | 61 | 9% |
Student > Postgraduate | 50 | 7% |
Student > Doctoral Student | 47 | 7% |
Other | 160 | 23% |
Unknown | 141 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 427 | 60% |
Agricultural and Biological Sciences | 26 | 4% |
Biochemistry, Genetics and Molecular Biology | 24 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 21 | 3% |
Chemistry | 8 | 1% |
Other | 37 | 5% |
Unknown | 168 | 24% |